

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A1	502,504	08-01-1893	Thoms	
	A2	1,792,156	02-10-1931	Fitzky	
	A3	2,046,375	07-07-1936	Goldstein et al.	
	A4	2,093,265	09-14-1937	Coffey et al.	
	A5	2,288,422	06-30-1942	Rohm	
	A6	2,649,476	08-18-1953	Martin	
	A7	2,683,082	07-06-1954	Hilli et al.	
	A8	2,722,544	11-01-1955	Martin	
	A9	2,745,874	05-15-1956	Schetty et al.	
	A10	2,781,330	02-12-1957	Downey	
	A11	2,797,214	06-25-1957	Bossard	
	A12	2,867,659	01-06-1959	Model et al.	
	A13	2,877,268	03-10-1959	Applegath et al.	
	A14	2,960,488	11-15-1960	Tamblin et al.	
	A15	2,973,386	02-28-1961	Weldon	
	A16	3,151,023	09-29-1964	Martin	
	A17	3,200,035	08-10-1965	Martin et al.	
	A18	3,230,141	01-18-1966	Frick et al.	
	A19	3,284,433	11-08-1966	Becker et al.	
	A20	3,424,760	01-28-1969	Helsley et al.	
	A21	3,424,761	01-28-1969	Helsley et al.	
	A22	3,424,762	01-28-1969	Helsley et al.	
	A23	3,547,940	12-15-1970	Brantley	
	A24	3,339,668	02-01-1972	Alles et al.	
	A25	3,945,059	02-29-1972	Brantley	
	A26	3,699,222	06-06-1972	Hauser	
	A27	3,699,550	09-05-1972	Schellenbaum et al	
	A28	3,743,498	07-03-1973	Brantley	
	A29	3,754,987	09-26-1973	Brantley	
	A30	3,823,161	07-09-1974	Lesser	
	A31	3,828,001	06-06-1974	Broad et al.	
	A32	3,880,945	01-14-1975	Nikowitz	
	A33	3,990,879	11-09-1976	Soper	
	A34	4,001,256	01-04-1977	Callahan et al.	
	A35	4,009,847	03-01-1977	Aldrich et al	
	A36	4,042,372	09-16-1977	Harper	
	A37	4,062,861	12-13-1977	Yukinaga et al.	
	A37a	4,063,928	12-20-1977	Johnston	
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in accordance with MPEP 609. Draw line through citation if not in accordance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to collect information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code* (if known)			
	A38	4,071,524	01-31-1978	Banitt	
	A39	4,103,022	07-25-1978	Sirrenberg et al	
	A40	4,111,980	09-05-1978	Yukinaga et al.	
	A41	4,111,683	09-05-1978	Singer	
	A42	4,116,671	09-25-1978	Yukinaga et al.	
	A43	4,173,037	11-06-1979	Nishiyama et al.	
	A44	4,173,038	11-06-1979	Nishiyama et al.	
	A45	4,183,654	01-15-1980	Crossley	
	A46	4,212,981	07-15-1980	Yukinaga et al.	
	A47	4,240,320	12-23-1980	Dickore et al.	
	A48	4,279,639	07-21-1981	Okamoto et al.	
	A48a	4,293,328	10-08-1981	Yukinaga et al.	
	A49	4,358,666	11-09-1982	Kruger	
	A50	4,405,944	09-20-1983	Kabbe et al	
	A51	4,410,697	10-18-1983	Török et al.	
	A52	4,437,878	03-20-1984	Acker et al.	
	A53	4,468,330	08-28-1984	O'Doherty et al.	
	A54	4,473,579	09-25-1984	Devries et al.	
	A55	4,499,097	02-12-1985	Tomeulok et al.	
	A56	4,511,571	04-18-1985	Böger et al.	
	A57	4,514,571	04-30-1985	Nakai et al.	
	A58	4,528,997	07-02-1985	O'Doherty et al.	
	A59	4,540,566	09-10-1985	Davis et al	
	A60	4,548,191	10-08-1985	Nishiyama et al	
	A61	4,587,240	05-06-1986	Hider et al.	
	A62	4,623,662	11-18-1986	DeVries	
	A63	4,643,849	02-17-1987	Hirai et al.	
	A64	4,740,520	04-26-1988	Hallenbach et al.	
	A65	4,790,063	07-26-1988	Hallenbach et al.	
	A66	4,775,763	10-04-1988	Dalton et al	
	A67	4,808,588	02-28-1989	King	
	A68	4,820,871	04-11-1989	Kissener et al.	
	A69	4,883,924	09-05-1989	Haga et al.	
	A69a	4,921,525	05-01-1990	Grossman et al.	
	A70	4,973,675	11-27-1990	Israel et al.	
	A70a	4,977,189	12-11-1990	Häusermann et al.	
	A71	4,983,605	01-08-1991	Kondo et al	
	A72	4,985,449	01-15-1991	Haga et al.	
	A72a	4,996,326	02-26-1991	Kristlison	
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS: SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No	Document Number Number - Kind Code * (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A73	5,036,072	07-30-1991	Nakajima et al.	
	A74	5,059,614	10-22-1991	Lepage et al.	
	A75	5,093,247	11-05-1991	Sekiya et al.	
	A76	5,096,907	03-24-1992	Kondo et al.	
	A77	5,100,663	03-31-1992	Schlesinger	
	A78	5,118,677	06-02-1992	Caufield	
	A79	5,118,678	06-02-1992	Kao et al.	
	A80	5,120,642	06-09-1992	Fatili et al.	
	A81	5,130,331	07-14-1992	Pascual	
	A82	5,151,344	09-29-1992	Abu et al.	
	A83	5,151,413	09-29-1992	Caulfield et al.	
	A84	5,162,360	11-10-1992	Creswell et al.	
	A84a	5,177,110	01-05-1993	Oechlein et al.	
	A85	5,185,353	02-09-1993	Creswell et al.	
	A86	5,256,790	10-26-1993	Nelson	
	A87	5,258,389	11-02-1993	Goulet et al.	
	A88	5,270,453	12-14-1993	Lemischka	
	A89	5,283,354	02-01-1994	Lemischka	
	A90	5,312,620	05-17-1994	Ashton et al.	
	A91	5,319,060	06-07-1994	Kamata et al.	
	A92	5,378,725	01-03-1995	Bonjoukian et al.	
	A93	5,399,566	03-21-1995	Katano et al.	
	A94	5,423,906	06-13-1995	Fringell	
	A95	5,429,918	07-04-1995	Seto et al.	
	A96	5,432,483	07-11-1995	Moriyama et al.	
	A97	5,441,347	06-15-1995	Dodge et al.	
	A98	5,447,957	06-05-1995	Adams et al.	
	A99	5,456,920	10-10-1995	Matoba et al.	
	A100	5,498,773	11-21-1995	Dodge et al.	
	A101	5,470,682	11-28-1995	Dixon et al.	
	A102	5,480,906	01-02-1996	Creamer et al.	
	A103	5,500,424	03-19-1996	Nagamine et al.	
	A104	5,508,283	04-16-1996	Forbes et al.	
	A105	5,547,966	06-20-1996	Atwal et al.	
	A106	5,559,137	06-24-1996	Adams et al.	
	A107	5,596,001	01-21-1997	Hamanaka	
	A108	5,507,719	01-28-1997	Freed et al.	
	A109	5,624,937	04-29-1997	Reel et al.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)				
	A110	5,859,612		08-12-1997	Monia	
	A111	5,658,903		08-19-1997	Adams et al.	
	A111a	5,667,226		09-19-1997	Janich	
	A112	5,696,138		12-09-1997	Olesen et al.	
	A113	5,699,581		12-16-1997	Kleermann et al.	
	A114	5,710,094		01-20-1998	Minami et al.	
	A115	5,721,237		02-24-1998	Myers et al.	
	A116	5,728,167		03-10-1998	Dodge et al.	
	A117	5,747,499		05-05-1998	Schnur et al.	
	A118	5,773,459		06-30-1998	Tang et al.	
	A119	5,777,097		07-07-1998	Lee et al.	
	A120	5,790,262		07-14-1998	Brent et al.	
	A121	5,780,483		07-14-1998	Widdowson et al.	
	A122	5,763,664		07-21-1998	Lee et al.	
	A123	5,786,392		07-28-1998	Krongrad	
	A123a	5,801,794		09-01-1998	Lehureau et al.	
	A124	5,807,676		09-15-1998	Armistead et al.	
	A125	5,807,691		09-15-1998	Bold et al.	
	A126	5,803,080		09-15-1998	Bell et al.	
	A127	5,814,646		09-29-1998	Heinz et al.	
	A128	5,869,043		02-09-1999	McDonnell et al.	
	A129	5,871,634		02-16-1999	Lee et al.	
	A130	5,898,044		03-23-1999	Widdowson et al.	
	A131	5,891,695		04-06-1999	Shiraishi et al.	
	A132	5,906,665		06-01-1999	Doi et al.	
	A133	5,919,773		07-06-1999	Monia et al.	
	A134	5,929,250		07-27-1999	Widdowson et al.	
	A135	5,955,366		09-21-1999	Lee et al.	
	A136	5,965,573		10-12-1999	Patric et al.	
	A137	6,004,965		12-21-1999	Brau et al.	
	A138	6,005,008		12-21-1999	Widdowson et al.	
	A139	6,015,506		01-19-2000	Widdowson et al.	
	A140	6,017,692		01-25-2000	Brent et al.	
	A141	6,020,345		02-01-2000	Vacher et al.	
	A142	6,022,564		02-08-2000	Mantio et al.	
	A143	6,025,151		02-15-2000	Peterson	
	A144	6,033,873		03-07-2000	McDonnell et al.	
	A145	6,040,339		03-21-2000	Yoshida et al.	

Examiner Signature

Date Considered

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 (if possible). ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A110	5,656,612	08-12-1997	Monia	
	A111	5,658,903	08-19-1997	Adams et al.	
	A146	6,043,374	03-28-2000	Widdowson et al.	
	A147	6,030,763	05-27-2000	Regan et al.	
	A148	6,093,742	07-25-2000	Salituro et al.	
	A149	6,103,692	08-15-2000	Avruch et al.	
	A150	6,114,517	09-05-2000	Monia et al.	
	A151	6,130,053	10-10-2000	Thompson et al.	
	A152	6,133,319	10-17-2000	Widdowson	
	A153	6,136,779	10-24-2000	Foulkes et al.	
	A154	6,143,764	11-07-2000	Kubo et al.	
	A155	6,147,107	11-14-2000	Dent et al.	
	A156	6,147,116	11-14-2000	Barbachyn et al.	
	A157	6,150,415	11-21-2000	Hammock et al.	
	A157a	6,159,901	12-12-2000	Kanno et al.	
	A158	6,174,001	01-16-2001	Mantlo et al.	
	A159	6,177,401	01-23-2001	Ullrich et al.	
	A160	6,178,369	01-23-2001	Takebayashi et al.	
	A161	6,130,631	01-30-2001	McMahon et al.	
	A162	6,180,675	01-30-2001	Widdowson et al.	
	A163	6,187,799	02-13-2001	Wood et al.	
	A164	6,193,965	02-27-2001	Karin et al.	
	A165	6,204,267	03-20-2001	Tang et al.	
	A166	6,210,710	04-03-2001	Skinner	
	A167	6,211,373	04-03-2001	Widdowson et al.	
	A168	6,213,530	04-17-2001	Widdowson	
	A169	6,228,881	05-08-2001	Regan et al.	
	A170	6,235,764	05-22-2001	Larson et al.	
	A170a	6,236,125	05-22-2001	Cudet et al.	
	A171	6,242,601	06-05-2001	Brau et al.	
	A172	6,262,113	07-17-2001	Widdowson et al.	
	A173	6,271,261	08-07-2001	Widdowson	
	A174	6,294,350	09-25-2001	Peterson	
	A175	6,297,391	10-02-2001	Cinillo et al.	
	A176	6,310,068	10-30-2001	Böttcher et al.	
	A177	6,316,492	11-13-2001	Bishop et al.	
	A178	6,319,921	11-20-2001	Cinillo et al.	
	A179	6,329,415	12-11-2001	Cinillo et al.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet **6** of **37**

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Paragraphs or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A180	6,333,341	12-25-2001	Mantlo et al.	
	A181	6,339,045	01-15-2002	Kanno et al.	
	A182	6,344,476	02-05-2002	Ranges et al.	
	A183	6,352,677	03-05-2002	Astles et al.	
	A184	6,358,525	03-19-2002	Guo et al.	
	A185	6,356,945	03-19-2002	Breitfelder et al.	
	A186	6,361,773	03-26-2002	Lee et al.	
	A187	6,372,773	04-16-2002	Regan	
	A188	6,372,933	04-16-2002	Baine et al.	
	A189	6,380,218	04-30-2002	Marfat et al.	
	A190	6,383,734	05-07-2002	Marshall et al.	
	A191	6,397,900	05-14-2002	Pevarello et al.	
	A192	6,391,917	05-21-2002	Petrie et al.	
	A193	6,409,666	06-11-2002	Hayakawa et al.	
	A194	6,414,011	07-02-2002	Hogenkamp et al.	
	A195	6,444,691	09-03-2002	Oremus et al.	
	A196	6,446,079	09-10-2002	Monia et al.	
	A197	6,479,516	11-12-2002	Astles et al.	
	A198	6,482,393	12-10-2002	Breitfelder et al.	
	A199	6,495,331	12-17-2002	Gelland et al.	
	A200	6,500,663	12-31-2002	Jim et al.	
	A201	6,511,800	01-29-2003	Singh	
	A202	6,511,997	01-28-2003	Minami et al.	
	A203	6,521,407	02-18-2003	Warren et al.	
	A204	6,521,692	02-19-2003	Ko et al.	
	A205	6,524,832	02-25-2003	Kulis et al.	
	A206	6,525,046	02-25-2003	Cirillo et al.	
	A207	6,525,065	02-25-2003	Caldwell et al.	
	A208	6,525,061	02-25-2003	Robinson et al.	
	A209	6,533,292	06-24-2003	Zhang et al.	
	A210	6,608,052	09-19-2003	Breitfelder et al.	
	A211	6,617,324	09-09-2003	Narasin et al.	
	A212	6,635,421	10-21-2003	Klagebrun et al.	
	A213	6,653,320	11-25-2003	Hayakawa et al.	
	A214	6,656,363	12-02-2003	Firestone et al.	
	A215	6,673,777	01-06-2004	Tracey et al.	
	A216	6,689,560	02-10-2004	Rapp et al.	
	A217	6,737,323	09-28-2004	Kubo et al.	

Examiner
Signature

Date
Considered

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 37

Complete if Known

Application Number 10/788,426
Filing Date March 1, 2004
First Named Inventor Jacques Dumas
Art Unit 1625
Examiner Name Heidi L. Reese
Attorney Docket Number BAYER-0044

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Paragraphs or Relevant Figures Appear
		Number - Kind Code (if known)			
	A217a	8,958,333	10-25-2005	Hayama et al.	
	A218	7,070,968	07-04-2006	Kule et al.	
	A219	7,235,576	06-28-2007	Riedl et al.	
	A220	7,253,286	08-07-2007	Funahashi et al.	
	A221	7,307,071	12-11-2007	Lyons et al.	
	A222	7,329,670	02-12-2008	Dumas et al.	
	A223	7,351,834	04-01-2008	Riedl et al.	
	A224	7,371,783	05-19-2008	Dumas et al.	
	A225	7,517,890	04-14-2009	Miller et al.	
	A226	7,528,255	05-06-2009	Riedl et al.	
	A226a	7,547,895	06-16-2009	Holzemann et al.	
	A227	7,557,129	07-07-2009	Scott et al.	
	A227a	7,605,261	10-20-2009	Deprez et al.	
	A227 b	7,612,062	11-03-2009	Funahashi et al.	
	A228	7,579,811	03-16-2010	Dumas et al.	
	B1	2001/0006075	07-05-2001	Wood et al.	
	B2	2001/0011195	06-02-2001	Riedl et al.	
	B3	2001/0011196	06-02-2001	Riedl et al.	
	B4	2001/0016659	09-23-2001	Riedl et al.	
	B5	2001/0027202	10-04-2001	Riedl et al.	
	B6	2001/0034447	10-25-2001	Riedl et al.	
	B7	2001/0035842	11-06-2001	Achen et al.	
	B8	2002/0037276	03-26-2002	Ptasznik et al.	
	B9	2002/0042517	04-11-2002	Uday et al.	
	B10	2002/0052763	05-30-2002	Machot et al.	
	B11	2002/0065263	05-30-2002	McMahon et al.	
	B12	2002/0065266	05-30-2002	Dumas et al.	
	B13	2002/0032255	06-27-2002	Eastwood	
	B14	2002/0035357	07-04-2002	Kim et al.	
	B15	2002/0065559	07-04-2002	Hashimoto et al.	
	B16	2002/0103053	08-01-2002	Ranges et al.	
	B16a	2002/0111495	08-15-2002	Magee et al.	
	B17	2002/0126321	09-12-2002	Widdowson et al.	
	B18	2002/0137774	09-26-2002	Riedl et al.	
	B19	2002/0181014	10-31-2002	Sadhu et al.	
	B20	2002/0185275	11-07-2002	Wu et al.	

Examiner
Signature

Date
Considered

*EXAMINER Initial # reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Paragraphs or Relevant Figures Appear
	B21	2002/0165349	11-07-2002	Kirsch et al.	
	B22	2002/0165354	11-07-2002	Dumas et al.	
	B23	2002/0173507	11-21-2002	Santora et al.	
	B24	2002/0189027	12-12-2002	Robinson et al.	
	B25	2002/0197256	12-26-2002	Grewal	
	B26	2003/0059284	04-10-2003	Keegan et al.	
	B26a	2003/0105091	06-05-2003	Riedl et al.	
	B27	2003/0125559	07-03-2003	Lyons et al.	
	B28	2003/0130309	07-10-2003	Moss et al.	
	B29	2003/0144278	07-31-2003	Riedl et al.	
	B30	2003/0157104	08-21-2003	Wakal	
	B30a	2003/0139605	07-24-2003	Riedl et al.	
	B31	2003/0181442	09-25-2003	Riedl et al.	
	B32	2003/0207970	11-06-2003	Dumas et al.	
	B33	2003/0207672	11-06-2003	Riedl et al.	
	B34	2003/0207914	11-06-2003	Dumas et al.	
	B34a	2003/0216356	11-20-2003	Dumas et al.	
	B35	2003/0216446	11-20-2003	Dumas et al.	
	B36	2003/0232400	12-18-2003	Radka et al.	
	B37	2003/0232765	12-18-2003	Carter et al.	
	B37a	2004/0023961	02-05-2004	Dumas et al.	
	B38	2004/0052890	03-19-2004	Kobayashi et al.	
	B39	2004/0096555	05-20-2004	Stratton et al.	
	B40	2004/0147541	07-29-2004	Lane et al.	
	B41	2004/0192770	09-30-2004	Kozikowski et al.	
	B42	2004/0197256	10-07-2004	Rogers et al.	
	B43	2004/0205605	10-21-2004	Kubo et al.	
	B43a	2004/0224937	11-11-2004	Furness et al.	
	B44	2004/0229937	11-18-2004	Dumas et al.	
	B45	2004/0235629	11-25-2004	Scott et al.	
	B46	2005/0032758	02-10-2005	Boyer et al.	
	B47	2005/0039031	02-17-2005	Dumas et al.	
	B48	2005/0039090	02-17-2005	Boyer et al.	
	B49	2005/0059703	03-17-2005	Wilhelm et al.	
	B49a	2005/0069963	03-31-2005	Lokshin et al.	
	B49b	2005/0096344	05-05-2005	Fraleigh et al.	
	B49c	2005/0175737	08-11-2005	Knobel	
	B50	2005/0256174	11-17-2005	Wood et al.	

Examiner
Signature

Date
Considered

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet **9** of **37**

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Paragraphs or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	B51	2005/0266266	12-29-2005	Flynn et al.	
	B52	2005/0058358	03-16-2006	Dumas et al.	
	B52a	2008/0241301	10-28-2006	Hoelzemann et al.	
	B52b	2006/0281762	12-14-2006	Stashie et al.	
	B53	2006/0078617	04-13-2006	Schueckler	
	B54	2005/0211738	09-21-2006	Mitchell et al.	
	B55	2005/0234931	10-19-2006	Biggs, III et al.	
	B56	2006/0247166	11-02-2006	Carter et al.	
	B57	2007/0020704	01-25-2007	Wilhelm et al.	
	B58	2007/0105142	05-10-2007	Wilhelm	
	B60	2007/0176434	08-02-2007	Etling et al.	
	B61	2007/0244120	10-18-2007	Dumas et al.	
	B62	2007/0265315	11-15-2007	Dumas et al.	
	B63	2003/0009527	01-10-2008	Dumas et al.	
	B64	2008/0027061	01-31-2008	Riedl et al.	
	B65	2006/0032679	02-07-2008	Riedl et al.	
	B67	2003/0045589	02-21-2008	Kelley	
	B69	2008/0109672	05-08-2008	Riedl et al.	
	B70	2006/0153623	06-26-2008	Riedl et al.	
	B71	2008/0194560	08-14-2008	Dumas et al.	
	B72	2003/0214545	09-04-2008	Lee et al.	
	B73	2003/0227828	09-18-2008	Dumas et al.	
	B74	2006/0242707	10-02-2008	Schuckler et al.	
	B76	2008/0269265	10-30-2008	Miller et al.	
	B77	2003/0300291	12-04-2008	Dumas et al.	
	B77a	2008/0311601	12-18-2008	Etling et al.	
	B77b	2008/0311604	12-18-2008	Etling et al.	
	B78	2009/0088146	03-12-2009	Wilhelm	
	B79	2009/0093526	04-09-2009	Miller et al.	
	B80	2009/0116266	05-07-2009	Riedl et al.	
	B82	2009/0192127	07-30-2009	Scheuring et al.	
	B84	2009/0215335	08-27-2009	Wilhelm	
	B84a	2009/0221010	09-03-2009	Etling et al.	
	B85	2009/0227637	09-10-2009	Weber et al.	
	B86	2009/0306020	12-10-2009	Scheuring et al.	
	B88	2010/0053033	03-11-2010	Wood et al.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ¹ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10788,426
 Filing Date March 1, 2004
 First Named Inventor Jacques Dumas
 Art Unit 1625
 Examiner Name Heidi L. Reese
 Attorney Docket Number BAYER-0044

Sheet 10 of 37

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ² - Number ³ - Kind Code ² (if known)					
	C1	WO-90/02112		03-08-1990	The Nutrasweet Company		
	C2	WO-92/03413		03-05-1992	Phone-Roulenec Rorer Limited et al.		
	C3	WO-92/05179		04-02-1992	American Home Products Corporation		
	C4	WO-93/04170		03-04-1993	The United States of America represented by The Secretary, Department Of Health And Human Services		
	C5	WO-93/18028		09-16-1993	SmithKline Beecham PLC et al.		
	C6	WO-93/24466		12-09-1993	Pfizer Inc. et al.		
	C7	WO-94/02136		02-03-1994	SmithKline Beecham Corp. et al.		
	C8	WO-94/02485		02-03-1994	SmithKline Beecham Corp. et al.		
	C9	WO-94/04541		03-03-1994	The UpJohn Co. et al.		
	C10	WO-94/14601		07-07-1994	SmithKline Beecham PLC et al.		
	C11	WO-94/18170		08-18-1994	SmithKline Beecham PLC et al.		
	C12	WO-94/22607		10-13-1994	Nau-Rosearch, A/S et al.		
	C13	WO-94/23755		10-27-1994	Board of Regents of the University of Nebraska		
	C14	WO-94/25012		11-10-1994	SmithKline Beecham PLC et al.		
	C15	WO-95/02136		01-19-1995	Mannesmann Aktiengesellschaft		abs
Examiner Signature		Date Considered					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ¹ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 11 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)				
	C16	WO-95/02591	01-26-1995	SmithKline Beecham Corporation et al.		
	C17	WO-95/07922	03-23-1995	SmithKline Beecham Corporation et al.		
	C18	WO-95/13067	05-18-1995	SmithKline Beecham Corporation et al.		
	C19	WO-95/14023	05-26-1995	Abbott Laboratories		
	C20	WO-95/18091	06-22-1995	Sandoz Ltd. et al.		
	C21	WO-95/19159	07-20-1995	Sugen, Inc.		
	C22	WO-95/31451	11-23-1995	SmithKline Beecham Corporation et al.		
	C23	WO-95/33456	12-14-1995	SmithKline Beecham Corporation et al.		
	C24	WO-95/33450	12-14-1995	SmithKline Beecham Corporation et al.		
	C25	WO-96/02112	01-25-1996	Thomson-CSF et al.		abs
	C26	WO-96/10559	04-11-1996	Fujisawa Pharmaceutical Co. Ltd.		
	C27	WO-96/13632	05-09-1996	Novo Nordisk A/S et al.		
	C28	WO-96/25157	08-22-1996	SmithKline Beecham Corporation et al.		
	C29	WO-96/40673	12-19-1996	Sugen, Inc.		
	C30	WO-96/40675	12-19-1996	Sugen, Inc.		
	C31	WO-96/41807	12-27-1996	Sandoz Ltd. et al.		
	C32	WO-97/03069	01-30-1997	Glaxo Group Limited et al.		
	C33	WO-97/09973	03-20-1997	The Regents of The University of California et al.		
	C34	WO-97/17267	05-15-1997	SGA Moynick AB et al.		
	C35	WO-97/17329	05-15-1997	Kim Beer Kabushiki Kaisha		abs

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 12 of 37

Complete if Known

Application Number 10/788,426
Filing Date March 1, 2004
First Named Inventor Jacques Dumas
Art Unit 1625
Examiner Name Heidi L. Reese
Attorney Docket Number BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)					
	C36	WO-97/29743		08-21-1997	Smith Kline Beecham Corporation et al.		
	C37	WO-97/30992		08-28-1997	Bristol-Myers Squibb Company		
	C38	WO-97/34146		09-18-1997	The General Hospital Corporation		
	C39	WO-97/40028		10-30-1997	Vertex Pharmaceuticals Incorporated		
	C40	WO-97/40842		11-06-1997	Eli Lilly and Company et al.		
	C41	WO-97/45400		12-04-1997	Neu-Rosearch A/S et al.		
	C42	WO-97/49399		12-31-1997	SmithKline Beecham Corporation et al.		
	C43	WO-97/49400		12-31-1997	SmithKline Beecham Corporation et al.		
	C44	WO-98/17207		04-30-1998	Synthes AG Chur et al.		
	C45	WO-98/17257		04-30-1998	Zymogenetics, Inc. et al.		
	C46	WO-98/20855		05-22-1998	The Picower Institute for Medical Research		
	C47	WO-98/22103		05-26-1998	Zeneca Limited et al.		
	C48	WO-98/22432		05-28-1998	Yamanouchi Pharmaceutical Co., Ltd.		abs
	C49	WO-98/32439		07-30-1998	SmithKline Beecham Corporation et al.		
	C50	WO-98/34929		08-13-1998	SmithKline Beecham Corporation et al.		
	C51	WO-98/45268		10-15-1998	Pfizer Products Inc. et al.		
	C52	WO-98/49150		11-05-1998	Takeda Chemical Industries, Ltd. et al.		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). † See Kinds of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ‡ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). † For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ‡ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16.1 if possible. † Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 13 of 37

Complete if Known

Application Number	10788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.†	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†6
		Country Code ¹ - Number ² - Kind Code ³ (if known)				
	C53	WO-98/52558	11-26-1998	Bayer Corporation et al.		
	C54	WO-98/52559	11-26-1998	Bayer Corporation et al.		
	C55	WO-98/52937	11-26-1998	G.D. Searle and Co. et al.		
	C56	WO-98/52941	11-26-1998	G.D. Searle and Co. et al.		
	C57	WO-98/56377	12-17-1998	SmithKline Beecham Corporation et al.		
	C58	WO-99/00357	01-07-1999	Vertex Pharmaceuticals Incorporated		
	C59	WO-99/00370	01-07-1999	Kureha Kagaku Kogyo Kabushiki Kaisha		abs
	C60	WO-99/20617	04-29-1999	Pharmacia & Upjohn Company et al.		
	C61	WO-99/21635	05-06-1999	Fujisawa Pharmaceutical Co., Ltd. et al.		
	C62	WO-99/23091	05-14-1999	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C63	WO-99/24035	05-20-1999	Bristol-Myers Squibb Company		
		WO-99/24398	05-20-1999	Zeneca Limited et al.		
	C65	WO-99/24635	05-20-1999	Advanced Technology Materials, Inc.		
	C66	WO-99/26657	06-03-1999	Medical University of South Carolina et al.		
	C67	WO-99/28305	06-10-1999	E.I. DuPont de Nemours & Company et al.		
	C68	WO-99/32106	07-01-1999	Bayer Corporation		
	C69	WO-99/32109	07-01-1999	Bristol-Myers Squibb Company		
	C70	WO-99/32110	07-01-1999	Bayer Corporation		
	C71	WO-99/32111	07-01-1999	Bayer Corporation		

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). † See Kind's Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. † Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). † For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. † Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. † Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 14 of 37

Complete if Known

Application Number 10/788,426
Filing Date March 1, 2004
First Named Inventor Jacques Dumas
Art Unit 1625
Examiner Name Heidi L. Reese
Attorney Docket Number BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)					
	C72	WO-99/32436		07-01-1999	Bayer Corporation		
	C73	WO-99/32437		07-01-1999	Slovak-Farma, A.S. et al.		
	C74	WO-99/32455		07-01-1999	Bayer Corporation		
	C75	WO-99/32453		07-01-1999	Bayer Corporation		
	C76	WO-99/33453		07-08-1999	Dalich Pharmaceuticals Co., Ltd. et al.		abs
	C77	WO-99/35132		07-15-1999	Glaxo Group Limited et al.		
	C78	WO-99/40673		08-12-1999	Moving Magnet Technologies (S.A.) et al.		abs
	C79	WO-99/55502		11-18-1999	Vertex Pharmaceuticals Incorporated et al.		
	C80	WO-99/62890		12-09-1999	Pfizer Products Inc. et al.		
	C81	WO-00/12497		03-09-2000	Scios Inc. et al.		
	C82	WO-00/17175		03-30-2000	Vertex Pharmaceuticals Incorporated et al.		
	C83	WO-00/19205		04-06-2000	Advanced Research and Technology Institute, Inc. et al.		
	C84	WO-00/28203		05-11-2000	Pharmacia & Upjohn S.P.A. et al.		
	C85	WO-00/27414		05-18-2000	BASF Aktiengesellschaft et al.		
	C86	WO-00/31238		06-02-2000	Genetec, Inc. et al.		
	C87	WO-00/34303		06-15-2000	Isa Pharmaceuticals, Inc. et al.		
	C88	WO-00/35454		06-22-2000	Du Pont Pharmaceuticals Company		
	C89	WO-00/35455		06-22-2000	Telik, Inc.		
	C90	WO-00/39101		07-06-2000	Astra Zeneca UK Limited et al.		
	C91	WO-00/39118		07-06-2000	Telikoku Hormone MFG Co. Ltd.		abs

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 15 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)				
	C92	WO-00/41998	07-20-2000	Bayer Corporation et al.		
	C93	WO-00/42012	07-20-2000	Bayer Corporation et al.		
	C94	WO-00/43356	07-27-2000	Kirin Boer Kabushiki Kaisha		abs
	C95	WO-00/43334	07-27-2000	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C96	WO-00/47577	08-17-2000	SmithKline Beecham PLC et al.		
	C97	WO-00/50425	08-31-2000	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C98	WO-00/55139	09-21-2000	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C99	WO-00/55152	09-21-2000	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C100	WO-00/56331	09-23-2000	Vertex Pharmaceuticals Incorporated et al.		
	C101	WO-00/71506	11-30-2000	Telik, Inc.		
	C102	WO-00/71532	11-30-2000	Pfizer Products Inc. et al.		
	C103	WO-01/04115	01-13-2001	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C104	WO-01/07411	02-01-2001	Banyu Pharmaceutical Co., Ltd.		abs
	C105	WO-01/09058	02-09-2001	Kirin Boer Kabushiki Kaisha et al.		
	C106	WO-01/12166	02-22-2001	Pharmacia & Upjohn S.P.A. et al.		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). ‡ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. † Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ‡ Applicant is to place a check mark here if English language. Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 16 of 37

Complete if Known

Application Number 10/788,426
Filing Date March 1, 2004
First Named Inventor Jacques Dumas
Art Unit 1625
Examiner Name Heidi L. Reese
Attorney Docket Number BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ²	- Number ³ - Kind Code ⁴ (if known)				
	C107	WO-01/39403		05-25-2001	Boehringer Ingelheim Pharmaceuticals, Inc. et al.		
	C108	WO-01/47892		07-05-2001	American Home Products Corporation		
	C109	WO-01/54723		08-02-2001	Sunnybrook Health Science Center et al.		
	C110	WO-01/54727		08-02-2001	The Van Kampen Group, Inc. et al.		
	C111	WO-01/57008		08-09-2001	BASF Aktiengesellschaft et al.		
	C112	WO-01/63403		08-30-2001	Sun Microsystems, Inc.		
	C113	WO-01/66099		09-13-2001	Astra Zeneca AB et al.		
	C114	WO-01/66540		09-13-2001	SmithKline Beecham P.L.C. et al.		
	C114a	WO-01/80843		11-01-2001	Supergen, Inc. et al.		
	C115	WO-02/05332		01-24-2002	General Electric Company		
	C116	WO-02/07747		01-31-2002	Joslin Diabetes Center, Inc. et al.		
	C117	WO-02/07772		01-31-2002	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C118	WO-02/10141		02-07-2002	Pfizer Products Inc. et al.		
	C119	WO-02/14281		02-21-2002	Cochran et al.		
	C120	WO-02/14311		02-21-2002	Amgen Inc. et al.		
	C121	WO-02/18345		03-07-2002	Pfizer Products Inc. et al.		
	C122	WO-02/24635		03-28-2002	Fujisawa Pharmaceutical Co., Ltd. et al.		
	C123	WO-02/25286		03-28-2002	The President and Fellows of Harvard College		
	C124	WO-02/32872		04-25-2002	Eisai Co., Ltd.		abs
	C125	WO-02/40445		05-23-2002	Novo Nordisk A/S		
	C126	WO-02/42012		05-30-2002	Brill		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language. Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 17 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)					
	C127	WO-02/44156		06-06-2002	Glaxo Group Limited et al.		
	C128	WO-02/44158		06-06-2002	Pfizer Products Inc. et al.		
	C129	WO-02/50091		06-27-2002	Glaxo Group Limited et al.		
	C130	WO-02/059081		08-01-2002	Padia et al.		
	C131	WO-02/059102		08-01-2002	Aventis Pharma S.A. et al.		abs
	C132	WO-02/060900		08-08-2002	Telik, Inc. et al.		
	C133	WO-02/062783		08-15-2002	Bayer Corporation et al.		
	C134	WO-02/070008		09-12-2002	Imclone Systems Incorporated et al.		
	C135	WO-02/076930		10-03-2002	Telik, Inc.		
	C136	WO-02/076977		10-03-2002	Bayer Corporation et al.		
	C137	WO-02/083628		10-24-2002	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C138	WO-02/083642		10-24-2002	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C139	WO-02/085857		10-31-2002	Bayer Corporation et al.		
	C140	WO-02/085859		10-31-2002	Bayer Corporation et al.		
	C141	WO-02/088090		11-07-2002	Vertex Pharmaceuticals Incorporated et al.		
	C142	WO-02/092576		11-21-2002	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C143	WO-03/004523		01-16-2003	Bayer Aktiengesellschaft et al.		
	C144	WO-03/005999		01-29-2003	Boehringer Ingelheim Pharmaceuticals, Inc.		
	C145	WO-03/047523		06-12-2003	Onyx Pharmaceuticals, Inc.		
	C146	WO-03/047579		06-12-2003	Bayer Corporation et al.		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. * Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet **18** of **37**

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)					
	C147	WO-03/056036		07-10-2003	Catalyst Biomedica Limited et al.		
	C148	WO-03/059373		07-24-2003	Ramot at Tel Aviv University Ltd. et al.		
	C149	WO-03/060111		07-24-2003	Catalyst Biomedica Limited et al.		
	C150	WO-03/065995		08-14-2003	Supergen, Inc. et al.		
	C151	WO-03/068223		08-21-2003	Bayer Corporation et al.		
	C152	WO-03/068228		08-21-2003	Bayer Corporation et al.		
	C153	WO-03/068229		08-21-2003	Bayer Corporation et al.		
	C154	WO-03/068746		08-21-2003	Bayer Corporation et al.		
	C155	WO-03/082272		10-09-2003	Chiron Corporation et al.		
	C156	WO-03/094626		11-20-2003	KMB Produktions AG et al.		abs
	C156a	WO-03/097854		11-27-2003	Sugen, Inc. et al.		
	C157	WO-03/099771		12-04-2003	Novartis AG et al.		
	C158	WO-2004/004720		01-15-2004	Astex Technology Limited et al.		
	C159	WO-2004/019941		03-11-2004	MERCK PATENT GMBH et al.		
	C160	WO-2004/037789		05-06-2004	MERCK PATENT GMBH et al.		
	C161	WO-2004/043574		05-27-2004	Dana-Farber Cancer Institute Inc. et al.		
	C162	WO-2004/045578		06-03-2004	NOVARTIS AG et al.		
	C163	WO-2004/052890		06-24-2004	ASTRAZENECA AB et al.		
	C164	WO-2004/078128		09-16-2004	Bayer Pharmaceuticals Corporation et al.		
	C165	WO-2004/078746		09-16-2004	Bayer Pharmaceuticals Corporation et al.		
	C166	WO-2004/078747		09-16-2004	Bayer Pharmaceuticals Corporation et al.		
	C167	WO-2004/078748		09-16-2004	Bayer Pharmaceuticals Corporation et al.		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. * Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 19 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)					
	C168	WO-2004/085399		10-07-2004	MERCK PATENT GMBH et al.		
	C169	WO-2004/085425		10-07-2004	AMGEN INC.		
	C170	WO-2004/108713		12-16-2004	Warner-Lambert Company LLC et al.		
	C171	WO-2004/108715		12-16-2004	Warner-Lambert Company LLC et al.		
	C172	WO-2004/113274		12-29-2004	Bayer Pharmaceuticals Corporation et al.		
	C173	WO-2005/000284		01-06-2005	Bayer Pharmaceuticals Corporation et al.		
	C174	WO-2005/002673		01-13-2005	Astex Technology Limited et al.		
	C175	WO-2005/004803		01-20-2005	MERCK PATENT GMBH et al.		
	C176	WO-2005/004864		01-20-2005	MERCK PATENT GMBH et al.		
	C177	WO-2005/005339		01-20-2005	MERCK PATENT GMBH et al.		
	C178	WO-2005/005434		01-20-2005	NOVARTIS AG et al.		
	C179	WO-2005/009367		02-03-2005	AMBIT BIOSCIENCES CORPORATION et al.		
	C180	WO-2005/009961		02-03-2005	Bayer Pharmaceuticals Corporation et al.		
	C181	WO-2005/011700		02-10-2005	SMITHKLINE BEECHAM CORPORATION et al.		
	C182	WO-2005/016252		02-24-2005	Ariad Gene Therapeutics, Inc. et al.		
	C183	WO-2005/019192		03-03-2005	MERCK PATENT GMBH et al.		abs
	C184	WO-2005/032543		04-14-2005	CHIRON CORPORATION et al.		
	C185	WO-2005/037273		04-26-2005	CHIRON CORPORATION et al.		
	C186	WO-2005/037285		04-26-2005	CHIRON CORPORATION et al.		

Examiner Signature

Date Considered

*EXAMINER Initial # reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ¹ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 20 of 37

Complete if Known

Application Number 10788,426
 Filing Date March 1, 2004
 First Named Inventor Jacques Dumas
 Art Unit 1625
 Examiner Name Heidi L. Reese
 Attorney Docket Number BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)					
	C187	WO-2005/037829		04-26-2005	MERCK PATENT GMBH et al.		abs
	C188	WO-2005/042520		05-12-2005	MERCK PATENT GMBH et al.		abs
	C189	WO-2005/047283		05-26-2005	MERCK PATENT GMBH et al.		abs
	C190	WO-2005/048948		06-02-2005	Ambit Biosciences Corporation et al.		
	C191	WO-2005/049003		06-02-2005	MERCK PATENT GMBH et al.		abs
	C191a	WO-2005/056764		06-23-2005	Compound Therapeutics, Inc. et al.		
	C192	WO-2005/058832		06-30-2005	MERCK PATENT GMBH et al.		
	C192a	WO-2005/059179		06-30-2005	Bayer Pharmaceutical Corporation et al.		
	C193	WO-2005/075425		08-18-2005	MERCK PATENT GMBH et al.		
	C194	WO-2005/089443		09-29-2005	The Penn State Research Foundation et al.		
	C195	WO-2005/110994		11-24-2005	Bayer Pharmaceuticals Corporation et al.		
	C196	WO-2006/026500		03-09-2006	Bayer Pharmaceuticals Corporation et al.		
	C197	WO-2006/028501		03-09-2006	Bayer Pharmaceuticals Corporation et al.		
	C198	WO-2006/027346		03-16-2006	ALTANA PHARMA AG et al.		
	C199	WO-2006/034797		04-06-2006	BAYER HEALTHCARE AG et al.		
	C200	WO-2006/094826		09-14-2006	BAYER HEALTHCARE AG et al.		
	C201	WO-2006/105844		10-12-2006	MERCK PATENT GMBH et al.		abs
	C202	WO-2006/125540		11-30-2006	BAYER HEALTHCARE AG et al.		
	C203	WO-2007/015947		02-08-2007	BAYER HEALTHCARE LLC et al.		
	C204	WO-2007/039403		04-12-2007	ALTANA PHARMA AG et al.		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ¹ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. ⁶ This collection of information is required by 37 CFR 1.57 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 21 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)					
	C205	WO-2007/039404		04-12-2007	ALTANA PHARMA AG et al.		
	C205a	WO-2007/047955		04-26-2007	BAYER HEALTHCARE LLC et al.		
	C206	WO-2007/053573		05-10-2007	Bayer Pharmaceuticals Corporation et al.		
	C207	WO-2007/054215		05-16-2007	BAYER HEALTHCARE AG et al.		
	C207a	WO-2007/056011		05-16-2007	BAYER HEALTHCARE LLC et al.		
	C207b	WO-2007/056012		05-16-2007	BAYER HEALTHCARE LLC et al.		
	C208	WO-2007/056094		05-24-2007	Bayer Pharmaceuticals Corporation et al.		
	C209	WO-2007/059154		05-24-2007	Bayer Pharmaceuticals Corporation et al.		
	C210	WO-2007/059155		05-24-2007	Bayer Pharmaceuticals Corporation et al.		
	C211	WO-2007/064872		06-07-2007	Bayer Pharmaceuticals Corporation et al.		
	C215	WO-2007/123722		11-01-2007	Bayer Pharmaceuticals Corporation et al.		
	C216	WO-2007/139930		12-06-2007	Bayer Pharmaceuticals Corporation et al.		
	C218	WO-2008/079968		07-03-2008	Bayer Pharmaceuticals Corporation et al.		
	C219	WO-2008/079972		07-03-2008	Bayer Pharmaceuticals Corporation et al.		
	C220	WO-2008/069399		07-24-2008	Bayer Pharmaceuticals Corporation et al.		
	D1	EP-0016371		10-01-1930	F. Hoffman-La Roche & Co. Aktiengesellschaft		abs

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 22 of 37

Complete if Known

Application Number	10788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)					
	D2	EP-0167214		05-02-1984	Duphar International Research B.V.		
	D3	EP-0116032		08-29-1984	BASF Aktiengesellschaft		abs
	D3a	EP-0192263		07-29-1992	Ishihara Sangyo Kaisha Ltd. et al.		
	D4	EP-0192263		08-27-1996	Ishihara Sangyo Kaisha Ltd. et al.		
	D5	EP-0202638		11-26-1986	Bayer AG		abs
	D6	EP-0230400		07-29-1987	CIBA-GEIGY AG		abs
	D6a	EP-0233559		08-26-1987	Ishihara Sangyo Kaisha Ltd. et al.		
	D7	EP-0233556		05-06-1992	Ishihara Sangyo Kaisha Ltd. et al.		
	D8	EP-0242666		10-26-1987	BASF Aktiengesellschaft		abs
	D9	EP-0264904		04-27-1988	Ishihara Sangyo Kaisha Ltd. et al.		
	D10	EP-0314615		05-03-1989	Ciba-Geigy AG		abs
	D11	EP-0335156		10-04-1989	Bayer AG		abs
	D12	EP-0359148		03-21-1990	Ishihara Sangyo Kaisha Ltd. et al.		
	D13	EP-0371676		08-06-1990	Novapharma		abs
	D14	EP-0375915		08-01-1990	Bayer AG		abs
	D15	EP-0330048		08-01-1990	Ishihara Sangyo Kaisha Ltd.		
	D16	EP-0381967		08-16-1990	Ishihara Sangyo Kaisha Ltd. et al.		
	D17	EP-0405233		01-02-1991	Mitsubishi Kasei Corporation		
	D18	EP-0425443		05-02-1991	Ciba-Geigy AG		abs
	D19	EP-0459587		12-04-1991	Novapharma		abs
	D20	EP-0502504		09-09-1992	Matsushita Electric Industrial Co., Ltd.		
	D21	EP-0509795		10-21-1992	American Home Products Corporation		
	D22	EP-0576305		10-11-1995	Hoechst Aktiengesellschaft		abs
	D23	EP-0690344		01-03-1996	Konica Corporation		
	D24	EP-0706220		05-01-1996	Canon Kabushiki Kaisha		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 23 of 37

Complete if Known

Application Number 10/788,426
Filing Date March 1, 2004
First Named Inventor Jacques Dumas
Art Unit 1625
Examiner Name Heidi L. Reese
Attorney Docket Number BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)					
	D24a	EP-0709225		05-01-1996	Nippon Paper Industries Co., Ltd.		
	D25	EP-0709225		08-05-1998	Nippon Paper Industries Co., Ltd.		
	D26	EP-0590433		08-25-1998	Kinn Beer Kabushiki Kaisha		
	D27	EP-1056725		12-06-2000	Bayer Corporation		
	D28	EP-1199306		04-24-2002	Banyu Pharmaceutical Co., Ltd.		
	D29	EP-1256567		11-13-2002	The Kitasato Institute		
	D30	EP-1537075		06-06-2005	Neurosearch A/S et al.		
	E1	CH-479557		11-28-1969	Dr. A. Wander AG		abs
	F1	CL-39988		06-04-1993	Ciba-Geigy AG		
	G1	CA 2 146 707		10-12-1995	Hoechst Aktiengesellschaft		
	G2	CA-2, 026, 535		04-28-1991	Ciba-Geigy AG		
	H1	DD-253997		02-10-1988	Karl-Marx-Universität, Büro Für Neuerungen und Schutzrechte		abs
	I1	DE-467014		11-14-1929	I.G. Farbenindustrie Akt.-Ges.		
	I2	DE-511488		10-16-1930	I.G. Farbenindustrie Akt.-Ges.		abs
	I3	DE-523437		04-02-1931	I.G. Farbenindustrie Akt.-Ges.		
	I4	DE-2436179		04-10-1996	Shionogi & Co. Ltd.		abs
	I5	DT-2501648		07-24-1975	The Dow Chemical Co.		abs
	I6	DT-2436179		02-06-1975	Shionogi & Co., Ltd.		abs
	I7	DE-3305966		08-23-1994	BASF AG		abs
	I8	DE-3529247		11-20-1998	Bayer AG		abs
	I9	DE-3540377		05-21-1987	Bayer AG		abs
	J1	FR-1,457,172		09-19-1998	Ferrania S.p.A.		abs
	K1	GB-771,333		03-27-1957	J.R. Geigy A.-G.		
	K2	GB-828,231		02-17-1960	J.R. Geigy A.-G.		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. * Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1490, Alexandria, VA 22313-1490.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 24 of 37

Complete if Known

Application Number 10/788,426
Filing Date March 1, 2004
First Named Inventor Jacques Dumas
Art Unit 1625
Examiner Name Heidi L. Reese
Attorney Docket Number BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)					
	K3	GB-921,682		03-20-1993	J.R. Geigy A.-G.		
	K4	GB-1,110,099		04-18-1993	Rhone-Poulenc S.A.		
	K4a	GB-1,111,554		05-01-1998	Societa Per Azioni Ferrania		
	K5	GB-1,590,870		06-10-1981	Shionogi Selyaku Kabushiki Kaisha.		
	L1	HU-P0004437		06-28-2001	Bayer Corporation		abs
	M1	IR-26555		01-13-2000	Bayer Corporation		abs
	N1	JP-44-2569		02-03-1999	Sankyo Co., Ltd. and Asahi Chem. Ind. Co., Ltd.		abs
	N2	JP-50-76072		06-21-1975	Shionogi Selyaku KK		abs
	N3	JP-50-77375		06-24-1975	Shionogi Selyaku KK		abs
	N4	JP-50-149688		11-29-1975	unknown		abs
	N5	JP-51-03170		06-01-1976	Shionogi Shinzaburo		abs
	N6	JP-51-80982		07-15-1976	Shionogi Selyaku KK		abs
	N7	JP-53-86053		07-29-1973	Shionogi Co. Ltd.		abs
	N8	JP-54-32488		09-03-1979	Otsuka Pharmaceutical Co. Ltd.		abs
	N9	JP-55-99152		07-25-1980	HOKKO CHEM. IND. CO.		abs
	N10	JP-55-124783		09-26-1980	Ishihara Mining & Chemical Co.		abs
	N11	JP-55-162772		12-16-1980	Shionogi & Co. Ltd.		abs
	N13	JP-57-53735		11-15-1982	Shionogi Selyaku KK		abs
	N14	JP-59-21626		05-02-1983	Shionogi Selyaku KK		abs
	N16	JP-61-20039		01-26-1986	Konishiroku Photo Ind. Co., Ltd.		abs
	N15	JP-63-214752		09-07-1988	Fuji Photo Film Co. Ltd.		abs
	N17	JP-64-9455		01-12-1989	Fuji Photo Film Co., Ltd.		abs
	N18	JP-1-102461		04-20-1989	Konica Corp.		abs
	N19	JP-1-132580		06-25-1989	Ciba Geigy AG		abs
	N20	JP-1-200254		08-11-1989	Konica Corp.		abs

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 25 of 37

Complete if Known

Application Number	10788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)					
	N21	JP-1-259360		10-17-1989	Konica Corp.		abs
	N22	JP-2-22550		01-25-1990	Konica Corp.		abs
	N23	JP-2-23337		01-25-1990	Konica Corp.		abs
	N24	JP-2-35450		02-05-1990	Konica Corp.		abs
	N25	JP-2-105146		04-17-1990	Konica Corp.		abs
	N26	JP-2-106048		04-19-1990	Konica Corp.		abs
	N27	JP-2-150840		05-11-1990	Konica Corp.		abs
	N28	JP-3-53247		03-07-1991	Fuji Photo Film Co Ltd.		abs
	N29	JP-3-144634		05-20-1991	Konica Corp.		abs
	N30	JP-3-198049		08-29-1991	Fuji Photo Film Co. Ltd.		abs
	N31	JP-6-75172		09-21-1994	Fuji Photo Film Co. Ltd.		abs
	N32	JP-8-301841		11-19-1995	Green Cross Corp. et al.		abs
	N33	JP-10-306078		11-17-1998	Mitsubishi Chemical Corp.		abs
	O1	LB-6124		01-12-2000	Bayer Corporation.		
	T-F1	CL-38888		08-04-1993	Ciba-Geigy AG		
	T-11	DE-437014		11-14-1929	I.G. Farbenindustrie Akt.-Ges.		
	T-13	DE-523437		04-02-1931	I.G. Farbenindustrie Akt.-Ges.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P7	Avruch et al. "Raf meets Ras: completing the framework of a signal transduction pathway." <i>TIBS</i> 19: July 1994, pp. 279-283	
	P9a	Baka et al., "A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis," <i>Expert Opinion Therapeutic Targets</i> , 2005, Vol. 10, No.5, pp. 567-576	
	P10	Salant et al. "Metabolic Considerations in Prodrug Design," Chapter Twenty-Three In: <i>Burger's Medicinal Chemistry and Drug Discovery</i> , 5th ed. John Wiley & Sons, Inc., New York, 1995: Vol. 1, pp. 949-952	
	P17	Berge et al. "Pharmaceutical Salts." <i>Journal of Pharmaceutical Sciences</i> . January 1977-1-19 Vol. 66, No. 1	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 (Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant). Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 26 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P22	Marlin Blanco "p38 MAPK signalling cascades: ancient roles and new functions," BioEssays, 22:637-645, 2000	
	P23	Foussard-Blancin, Odette, "Comparative pharmacological study of substituted carboxamides upon central nervous system," Ann Pharm. Fr. (1982), 40 (4), pp. 339-350	
	P25	Bollag et al., "Raf pathway inhibitors in oncology," Current Opinion in Investigational Drugs (2003) 4(12): pp. 1436-1441.	
	P26	Bolton et al., "Chapter 17. Ras Oncogene Directed Approaches In Cancer Chemotherapy," Annual Reports In Medicinal Chemistry, Vol. 29, 1994, pp. 165-174	
	P28a	Boyer, S.J., "Small Molecule Inhibitors of KDR (VEGFR-2) Kinase: An Overview of Structure Activity Relationships," Current Topics in Medicinal Chemistry, 2002, Vol. 2, pp. 973-1000	
	P50	Copérat et al., "A Simple And Efficient Method for the Preparation of Pyridine-N-oxides II," Tetrahedron Letters Elsevier Science Ltd., Pergamon Press, Oxford, UK 1998, Vol. 39, pp. 761-764	
	P53a	Crump, Michael, "Inhibition of raf kinase in the treatment of acute myeloid leukemia," Medline Abstract ISSN:1551-8125, Current Pharmaceutical Design, Vol. 8, Issue 25, 2002, pp. 2243-2246	
	P57	Daum et al., "The ins and outs of Raf kinases," TIBS 19, November 1994, pp. 474-480	
	P66	Dumas, J., "Protein kinase inhibitors from the urea class," Curr. Opin. in Drug Discovery and Dev., 5(s):718-727, 2002	
	P67	Dumas et al., "Discovery of a New Class of p38 Kinase Inhibitors," Bioorganic & Medicinal Chemistry Letters Vol. 10, (2000), pp. 2047-2050	
	P68	Dumas et al., "1-Phenyl-5-pyrazolyl Ureas: Potent and Selective p38 Kinase Inhibitors," Bioorganic & Medicinal Chemistry Letters, 2000, Vol. 10, pp. 2051-2054	
	P68a	Dumas, J., "Growth factor receptor kinase inhibitors: Recent progress and clinical impact," Current Opinion in Drug Discovery & Development, 2001, Vol. 4, No. 4, pp. 378-389	
	P68b	Dumas, J., "Protein kinase inhibitors: emerging pharmacophores 1997-2000," Expert Opinion on Therapeutic Patents (2001) Vol. 11, No. 3, pp. 405-429	
	P68c	Dumas et al., "Orally Active p38 Kinase Inhibitors from the Urea Class," Poster, 222nd American Cancer Society National Meeting 2001, Med 1256, 1 page	
	P68d	Dumas, J., "Raf Kinase Inhibitors," Expert Opinion on Therapeutic Patents. Vol. 8, No. 12 pp. 1749-1750, 1998	
	P69	Dumas et al., "Recent developments in the discovery of protein kinase inhibitors from the urea class," Current Opinion in Drug Discovery & Development, 2004, Vol. 7, Number 5, pp. 600-615	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	27	of	37	Complete if Known
				Application Number
				Filing Date
				First Named Inventor
				Art Unit
				Examiner Name
				Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	P22	Martin-Blanco, "p38 MAPK signalling cascades: ancient roles and new functions," <i>BioEssays</i> , 22:637-645, 2000		
	P70	Dumas et al., "Synthesis and Pharmacological Characterization of a Potent, Orally Active p38 Kinase Inhibitor," <i>Bioorganic & Medicinal Chemistry Letters</i> , 2002, Vol. 12, pp. 1559-1562		
	P107	Gura, "Systems for identifying new drugs are often faulty," <i>Science</i> , 1997, Vol. 276, (5340), pp. 1041-1042, MEDLINE with Full Text		
	P147	Kubo et al., "Synthesis and structure-activity relationship of quinoxaline-urea derivatives as novel orally active VEGF receptor tyrosine kinase selective inhibitors," <i>Proceedings of the American Association of Cancer Res.</i> , 2002, Vol. 43, p. 182, abstract no. 913		
	P149	Kumar et al., "Drugs targeted against protein kinases" <i>Expert Opin. Emerging Drugs</i> 6(2):303-315 (2001)		
	P166	Lyons et al., "Discovery of a novel Raf kinase inhibitor," <i>Endocrine-Related Cancer</i> , 2001, Vol. 8, pp. 219-225		
	P224	Regan et al., "Pyrazole Urea-Based Inhibitors of p38 MAP kinase: From Lead Compound to Clinical Candidate," <i>J. Med. Chem.</i> 45:2994-3008, 2002		
	P248	Smith et al., "Discovery of Heterocyclic Ureas as a New Class of Raf Kinase Inhibitors: Identification of a Second Generation Lead by a Combinatorial Chemistry Approach," <i>Bioorganic & Medicinal Chemistry Letters</i> , 2001, Vol. 11, pp. 2775-2778		
	P249	Smith et al., (Abstract) "Recent Advances in the Research and Development of RAF Kinase Inhibitors," <i>Current Topics in Medicinal Chemistry</i> 6(11):1071-1099 (2006)		
	P276	Thalmattam et al., "3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies," <i>Bioorganic & Medicinal Chemistry</i> , 2004, Vol. 12, pp. 6415-6425		
	P278	Thompson et al., "Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery," <i>Curr. Opin. Pharmacol.</i> , August 2005, Vol. 5, Number 4, pp. 350-356		
	P284	Wilson et al., "The structural basis for the specificity of pyridylimidazole inhibitors of p38 MAP kinase," <i>Chemistry & Biology</i> , 1997, Vol. 4, Number 6, pp. 423-431.		
	P312	Kubo et al., "Synthesis and Structure-Activity Relationship of Quinoxaline-Urea Derivatives as Novel Orally Active VEGF Receptor Tyrosine Kinase Selective Inhibitors," <i>Proceedings of the American Association of Cancer Res.</i> , 2002, Vol. 43, p. 182, abstract no. 913		
	P313	Reddi et al., "4865 Potent Raf Kinase Inhibitors from the Diphenylurea Class: Structure Activity Relationships," <i>Proceedings of the American Association for Cancer Research</i> , Vol. 42, March 2001 (2001-03), page 923, 92nd Annual Meeting of the American Association for Cancer Research: New Orleans, LA, USA: March 24-28, 2001		
	P315	Abstract of DE 3305866 A1, August 23, 1984, BASF AG et al		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 28 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P316	Abstract of EP 4931 A (Equivalent 4,240,820), Bayer AG, 1 page	
	P317	Abstract of EP 16371 (1990), 1 page, Hottmann-La Roche AG	
	P318	Abstract of EP 16371, October 1, 1990, 1 page	
	P319	Abstract of EP 116932, August 29, 1984, 2 pages.	
	P320	Abstract of EP 116932, (1984), 2 pages, BASF AG	
	P321	Abstract of EP 0202538, (1996), 3 pages	
	P322	Abstract of EP 0202538 A1, "Growth Promoting Agents, November 26, 1986, 4 pages, Bayer AG	
	P323	Abstract of EP 0405233A1. Mitsubishi Kasei Corp., 2 pages	
	P324	Abstract of EP 0405233A1, Tetsuo Sekiya et al., 1 page	
	P325	Abstract of EP 0676395A2, (1995), 3 pages, Hoechst AG	
	P326	Abstract of EP 676395, (U.S. equivalent 5,698,561), December 16, 1997, 1 page	
	P327	Patent Abstracts of Japan 02-022650, 01-25-1990, 2 pages, Konica Corp	
	P328	esp@comet Abstracts of Japan 02-022650, 01-25-1990, 1 page	
	P329	Patent Abstracts of Japan 02-023337, 01-25-1990 2 pages Konica Corp	
	P329a	Patent Abstracts of Japan 63-214752, 09-07-1993, 2 pages, family member of JP 6-07512 B4, Fuji Photo Film Co. Ltd.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial # reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 29 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P330	esp@cenet Abstract of Japan 02-023337. 1 page	
	P331	Abstract of JP 55152772 A2. Preparation of Substituted Acetic Acid Derivatives, Shiongi & Co., Ltd. December 1980, 1 page	
	P332	Esp@cenet Abstract of WO 9622103. 28 May 1996. Philip Hedge et al.	
	P332a	Abstract of WO 9822098 A2. QLT Phototherapeutics Inc. et al., 05-28-1996, 1 page	
	P333a	Abstract of WO 9622103 A1, Zeneca Limited, published 05-28-1996, 1 page	
	P333b	Abstract of WO 9822559 A1, Bayer Corp. et al., published 11-26-1998, 1 page	
	P333c	Abstract of WO 9822562 A1, Verkaik, MSE, et al., published 11-26-1998, 1 page	
	P333d	Abstract of WO 9900557 A1, Verlaex Pharm. Inc., published 01-07-1999, 1 page	
	P333e	Abstract of WO 9900364 A1, Pharmacia & Upjohn S.P.A. et al., published 01-07-1999, 1 page	
	P333f	Abstract of WO 9932058 A2, Janssen Pharm NV, published 07-01-1999, 1 page	
	P333g	Abstract of WO 9932106 A1, Bayer Corp., published 07-01-1999, 1 page	
	P333h	Abstract of WO 9932148 A1, Beth Israel Deaconess Medical Center et al., pub. 07-01-1999, 1 page	
	P333i	Abstract of WO 9932436 A1, Bayer Corp., published 07-01-1999, 1 page	
	P333j	Abstract of WO 9932455 A1, Bayer Corp., published 07-01-1999, 1 page	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 30 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P333k	Abstract of WO 9932457 A1, Hoechst Marion Roussel Deutschland GmbH et al. published 07-01-1999, 1 page	
	P334	Caplus 72:79046, Abstract of CH 479557. "Tuberculostatic and cancerostatic polybasic ureas." Dr. A. Wander, October 15, 1999, 6 pages	
	P335	Caplus 84:180049, Abstract JP 56029571, "Substituted acetic acid derivatives," Hamada, Yoshinori et al., July 10, 1991, 1 page	
	P336	Caplus 84:43857, Abstract JP 56021626. "Alkanolic acid derivatives containing a pyridine ring," Maeda, Ryozi et al., May 2, 1993, 1 page	
	P337	Caplus 56:72448, Abstract JP 57053765. "Pyridine derivatives," Maeda, Ryozi et al., November 15, 1982, 1 page	
	P339	Caplus 98:78152, Abstract of JP 57185219, "Antitumor benzophenone derivatives," November 15, 1982, 1 page, Chugai Pharmaceutical Co., Ltd.	
	P340	Caplus 113:108314, Abstract of JP 2022650, "Silver halide color photographic material containing a cyan coupler of 2-ureido-phenol type to improve dye developability and remove leuco cyan dyes," Noboru Mizukura et al. January 25, 1990, 1 page	
	P341	Caplus 113:142130, Abstract of JP 2023337, "Silver halide photographic material containing phenolic cyan coupler a colorless cyan coupler," Toshihiko Yagi et al., January 25, 1990, 1 page	
	P346	Caplus 127:341371, "Preparation of quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation," Kazuo Kubo et al., May 15, 1997, WO 97/17329	
	P347	Caplus 131:58558k, "Inhibition of rat kinase using symmetrical and unsymmetrical substituted diphenyl ureas," Miller, Scott, et al. July 1, 1999, WO 99 32,436	
	P348	Caplus 131:73649b, "Preparation of pyrazolyl aryl ureas and related compounds as p38 kinase inhibitors," Jacques Dumas et al., July 1, 1999, WO 99/32110	
	P352	"Beilstein number" Collection, 28 pp. (1997)	
	P353	"Beilstein number" Collection, 4 pp. (1997)	
	P354	Derwent World Patents Index Search pp. 20-26, (1997)	
	P355	Dumas, J. "CAS Substructure," May 6, 1997, pp. 1-29	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial # reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	31	of	37	Complete if Known
				Application Number
				Filing Date
				First Named Inventor
				Art Unit
				Examiner Name
				Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P356	Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pp. 1-19	
	P357	Scott, Bill, "Substructure #2," November 25, 1997, pp. 1-3	
	P358	Scott, Bill, "Substructure Search," December 2, 1997, pp. 1-49	
	P359	Substructure Search, pp. 1-29, (1997)	
	P360	Wild, Hanno, "Substructure #1," search, pp. 1-150, 1998	
	P361	A "Notice of References Cited" from the USPTO for U.S. application 03/995,749, filing date of 12/22/97, Inhibition of P38 Kinase Using Symmetrical and Unsymmetrical Diphenyl Ureas, 2 pages	
	P362	A "Notice of References Cited" from the USPTO for U.S. application 09/063,369, filing date of 5/22/98, Patent 6187799 issued 2/13/2001, Inhibition of Raf Kinase Activity Using Aryl Ureas, 1 page	
	P363	A "Notice of References Cited" from the USPTO for U.S. application 09/425,228, filing date of 10/22/99, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 3 pages	
	P364	A "Notice of References Cited" from the USPTO for U.S. application 09/425,229, filing date of 10/22/99, Omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, 1 page	
	P365	A "Notice of References Cited" from the USPTO for U.S. application 09/458,015, filing date of 12/10/1999, Inhibition Of p38 Kinase Using Symmetrical And Unsymmetrical Diphenyl Ureas, 1 page	
	P366	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232, filing date of 12/27/99, Patent 7329670 issued 2/12/2005, Inhibition of Raf Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas, 1 page	
	P367	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232, filing date of 12/27/99, Patent 7329670 issued 2/12/2005, Inhibition of Raf Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas, 1 page	
	P368	A "Notice of References Cited" from the USPTO for U.S. application 09/773,604, filing date of 2/2/01, Publication No. US 2001-0034447-A1, Publication Date 10/25/01, Omega-carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page	
	P369	A "Notice of References Cited" from the USPTO for U.S. application 09/773,650, filing date of 2/2/01, Publication No., US 2001-0011135 A1, Publication Date: August 2, 2001, Omega-carboxyaryl Substituted Diphenyl Ureas As Raf Kinase inhibitors, 1 page	
	P370	A "Notice of References Cited" from the USPTO for U.S. application 09/773,672, filing date of 2/2/01, Publication No. : US 2001-0016659 A1, Publication Date: August 23, 2001, Omega-carboxyaryl substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial # reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 32 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAVER-0044

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	P371	A "Notice of References Cited" from the USPTO for U.S. application 09/773,075, filing date of 2/2/01, Publication No.: US 2001-0011135-A1, Publication Date: August 2, 2001, Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page	
	P372	A "Notice of References Cited" from the USPTO for U.S. application 09/776,935 filing date of 12/22/93, Inhibition Of p38 Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, 1 page	
	P373	A "Notice of References Cited" from the USPTO for U.S. application 09/776,936, filing date of 12/22/98, Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas, 1 page	
	P374	A "Notice of References Cited" from the USPTO for U.S. application 09/777,920, filing date of 2/7/01, Inhibition of RAF kinase using quinolyl, isquinolyl or pyridyl ureas, 1 page	
	P375	A "Notice of References Cited" from the USPTO for U.S. application 09/048,915, filing date of 9/10/01, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 1 page	
	P376	A "Notice of References Cited" from the USPTO for U.S. application 10/042,226, filing date of 01/11/2002, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 1 page	
	P376a	Co-pending application Serial No. 09/458,014, filed December 10, 1999, Dumas et al.	
	P377	Abandoned application Serial No. 09/776,935 filed December 22, 1998, Dumas et al.	
	P378	Co-pending application Serial No. 09/776,936 filed December 22, 1998, Miller et al.	
	P379	Issued application Serial No. 09/886,227 filed July 12, 2000, Riedl et al., issued as 7351634, 4/1/2008	
	P380	Co-pending application Serial No. 09/993,647 filed November 27, 2001, Riedl et al., published as 2003-0181442, 9/25/2003	
	P381	Issued application Serial No. 10/060,366 filed February 1, 2002, Miller et al., patent 7517890, issued 4/14/2009, also published as 2004-0102636, 5/27/2004	
	P382	Issued application Serial No. 10/071,248 filed February 11, 2002, Riedl et al., patent 7528255, issued 5/5/2009, also published as 2003-139605, 7/24/2003	
	P383	Abandoned application Serial No. 10/088,417 filed March 4, 2002, Riedl et al., published as 2003-0105091, 6/5/2003	
	P384	Abandoned application Serial No. 10/125,369 filed April 19, 2002, Dumas et al., published as 2003-0207914, 11/5/2003	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. * Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

Sheet 33 of 37

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P385	Abandoned application Serial No. 10/308,167 filed December 3, 2002, Garner et al., published as 2003-0232755, 12/16/2003	
	P386	Abandoned application Serial No. 10/361,844 filed February 11, 2003, Dumas et al., published as 2004-0023961, 2/5/2004	
	P387	Abandoned application Serial No. 10/361,850 filed February 11, 2003, Dumas et al., published as US 2003-0216396, 11/20/2003	
	P388	Co-pending application Serial No. 10/361,859 filed February 11, 2003, Dumas et al., published as 2003-0218445, 11/20/2003	
	P389	Co-Pending U.S. Patent Application No. 10/095,985 filed July 22, 2004, Boyer et al., published as US 2005-0030300, 2/17/2005	
	P389b	Co-Pending U.S. Patent Application No. 11/532,548 filed October 31, 2007, Dumas et al.,	
	P390	Co-Pending U.S. Patent Application No. 12/034,662 filed May 7, 2008, Saninier et al., published as 2010-0035883, 2/11/2010	
	P391	Co-Pending U.S. Patent Application No. 12/086,454 filed June 12, 2008, Weber et al.	
	P391a	Co-Pending U.S. Patent Application No. 12/093,515 filed November 13, 2008, Wilhelm et al.	
	P392	Co-Pending U.S. Patent Application No. 12/096,811 filed May 30, 2006, Smith et al.	
	P393	Co-Pending U.S. Patent Application No. 12/156,524 filed June 20, 2008, Smith et al.	
	P394	Co-Pending U.S. Patent Application No. 12/294,979 filed September 29, 2008, Wilhelm et al.	
	P394a	Co-Pending U.S. Patent Application No. 12/421,690 filed April 10, 2009, Dumas et al.,	
	P395	Co-Pending U.S. Patent Application No. 12/444,974 filed April 9, 2009, Grunenberg et al.	
Examiner Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

Sheet 34 of 37

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P396	Co-Pending U.S. Patent Application No. 12/514,129 filed May 8, 2006, Grunenberg et al.	
	P397	Co-Pending U.S. Patent Application No. 12/514,715 filed May 13, 2006, Siehl et al.	
	P398	Co-Pending U.S. Patent Application No. 12/520,618 filed June 22, 2009, Smith et al.	
	P399	Co-Pending U.S. Patent Application No. 12/520,609 filed June 22, 2009, Smith et al.	
	P400	Co-pending U.S. Patent Application No. 12/523,852 filed July 17, 2009, Wilhelm et al	
	P401	Co-pending U.S. Patent Application No. 12/523,697 filed July 17, 2009, Wilhelm et al	
	P402	Co-Pending U.S. Patent Application No. 12/628,735 filed December 1, 2009, Dumas et al.	
	P402a	Co-Pending U.S. Patent Application No. 12/692,345 filed January 25, 2010, Dumas et al.	
	P403	Co-Pending Application PCT/US09/51506, filed October 21, 2009, Carol Pena	
	P404	International search report for International Application No. PCT/US98/10375 dated 9/3/98, Inhibition Of p38 Kinase Activity By Aryl Ureas, publication No. 98/52558, publication date 11/28/1998, 1 page	
	P405	International search report for International Application No. PCT/US98/10376 dated 7/30/98, Raf Kinase Inhibitors, publication No. WO 98/52559, publication date 11/28/1998, 1 page	
	P406	International search report for International Application No. PCT/US98/26078 dated 4/2/99, Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas, publication no. WO 99/32108, publication date 7/1/1999, 2 pages	
	P407	International search report for International Application No. PCT/US98/26079 dated 4/12/99, Inhibition Of p38 Kinase Activity Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. WO 99/32110, publication date 7/1/1999, 1 page	
	P408	International search report for International Application No. PCT/US98/26080 dated 4/12/99, Inhibition Of p38 Kinase Using Substituted Heterocyclic Ureas, publication No. WO 99/32111, publication date 7/1/1999, 1 page	
Examiner Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	35	of	37	Complete if Known
				Application Number
				Filing Date
				First Named Inventor
				Art Unit
				Examiner Name
				Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published.		T ²
	P409	International search report for International Application No. PCT/US96/26081 dated 4/2/99, INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS, publication No. WO 96/32439, publication date 7/1/1999, 1 page		
	P410	International search report for International Application No. PCT/US96/26082 dated 5/12/99, Inhibition Of Raf Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. WO 96/32455, publication date 7/1/1999, 1 page		
	P411	International search report for International Application No. PCT/US96/27265, dated 3/2/99, Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas, publication No. WO 99/32453, publication date 7/1/99, 1 page		
	P412	International search report for International Application No. PCT/US96/00648 dated 6/29/00, Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors, publication No. WO 00/42012 A1, publication date 7/20/2000, 2 pages		
	P413	International search report for International Application No. PCT/US00/00788 dated 5/16/00, Omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, publication No. WO 00/41699 A1, publication date 7/20/2000, 1 page		
	P414	International search report for International Application No. PCT/US02/12064 dated 9/20/02, HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS, publication No. 02/085859, publication date 10/31/2002, 2 pages		
	P415	International search report for International Application No. PCT/US02/12066 dated 9/27/02, Inhibition Of Raf Kinase Quinolyl, Isoquinolyl Or Pyridyl Ureas, publication No. 02/085857, publication date 10/31/2002, 2 pages		
	P416	Supplemental search report from the EPO for European application EP 96963909.3 dated 3/30/01, Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas, publication No. 1049664, publication date 7/1/1999, granted 3/16/2005, 4 pages		
	P417	Supplemental search report from the EPO for European application EP 96963810.1 dated 12/21/00, Inhibition Of Raf Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. 1059725, publication date 7/1/1999, granted 6/7/2008, 4 pages		
	P418	Supplemental search report from the EPO for European application EP 98965681.8 dated 12/21/00, Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas, publication No. 1047418, publication date 7/1/1999, granted 7/27/2005, 8 pages		
	P419	Supplemental search report from the EPO for European application EP 00063239.2 dated 8/7/02, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, publication No. EP 1140840, published 7/20/2000, granted 3/22/2008, 6 pages		
	P420	Supplemental search report from the EPO for European application EP 00065697.1 dated 2/7/05, Omega-Carboxyaryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, publication No. EP 1158985, 7/20/2000, 9 pages		
	P431	English abstract of JP 10-306078, 1996-11-17, Patent Abstracts of Japan, 2 pages		
	P432	English abstract of JP 09-301841, 1996-11-19, Patent Abstracts of Japan, 2 pages		
Examiner Signature	Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

Sheet 36 of 37

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P433	English abstract of JP 03-198049, 1991-08-29, Patent Abstracts of Japan, 1 page	
	P434	English abstract of JP 03-144634, 1991-06-20, Patent Abstracts of Japan, 1 page	
	P435	English abstract of JP 03-053247, 1991-03-07, Patent Abstracts of Japan, 1 page	
	P436	English abstract of JP 02-150640, 1990-05-11, Patent Abstracts of Japan, 1 page	
	P437	English abstract of JP 02-108048, 1990-04-19, Patent Abstracts of Japan, 1 page	
	P438	English abstract of JP 02-105146, 1990-04-17, Patent Abstracts of Japan, 1 page	
	P439	English abstract of JP 02-035450, 1990-02-06, Patent Abstracts of Japan, 1 page	
	P440	English abstract of JP 01-290254, 1989-08-11, Patent Abstracts of Japan, 1 page	
	P441	English abstract of JP 01-259390, 1989-10-17, Patent Abstracts of Japan, 2 pages	
	P442	English abstract of JP 01-102461, 1989-04-20, Patent Abstracts of Japan, 1 page	
	P443	English abstract of JP 06-120039, 1994-04-28, Patent Abstracts of Japan, 1 page	
	P444	English abstract of JP 05-180982, 1993-07-23, Patent Abstracts of Japan, 1 page	
	P445	English abstract of JP 05-163170, 1993-06-29, Patent Abstracts of Japan, 1 page	
	P446	English abstract of JP 05-077375, 1993-03-30, Patent Abstracts of Japan, 1 page	
Examiner Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 37 of 37

Complete if Known

Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P447	English abstract of JP 05-076072, 1993-03-26, Patent Abstracts of Japan, 2 pages	
	P448	English abstract of JP 50-149668 A and JP 56-29871 B, Derwent World Patents Index, Dialog File No. 351, Acc No. 1488399, 3 pages	
	P449	English abstract of JP 53-085033, 1978-07-20, Patent Abstracts of Japan, 1 page	
	P450	English abstract of JP 54-032488, 1979-03-09, Patent Abstracts of Japan, 1 page	
	P451	English abstract of JP 55-098152, 1980-07-25, Patent Abstracts of Japan, 1 page	
	P452	English abstract of JP 64-009455, 1989-01-12, Patent Abstracts of Japan, 1 page	
	P453	English abstract of JP 02-023337, 1970-03-09, Patent Abstracts of Japan, 2 pages	
	P454	English abstract of EPA 0379915/EP-A1, 1990-08-01, 2 pages	
	P455	English abstract of DD 253967 A, 1989-02-10, 1 page	
	P456	English abstract of DE511468, European Patent Office, 2 pages; 10/30/1930	
	P457	Co-Pending U.S. Patent Application No. 12/819,913, filed November 17, 2009, Ranges et al	
	T-P3a	Arzneimitteltherapie, "Socatenib" October 6, 2006, Auflage 15498, 7 pages English translation	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.